

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

CONFIRMATION NO. ATTORNEY DOCKET NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR GJE-48D1 3776 07/11/2003 Seppo Yla-Herttuala 10/618,570 **EXAMINER** 23557 01/13/2006 7590 LI, RUIXIANG

SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO BOX 142950 GAINESVILLE, FL 32614-2950

ART UNIT PAPER NUMBER 1646

DATE MAILED: 01/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
Office Action Summary		10/618,570	YLA-HERTTUALA ET AL.
		Examiner	Art Unit
		Ruixiang Li	1646
	The MAILING DATE of this communication app	_	
Period fo	r Reply		
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DA assions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status			
1)	Responsive to communication(s) filed on	_•	
2a)□	This action is FINAL 2b)⊠ This	action is non-final.	
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is		
	closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.
Dispositi	on of Claims		
5) 6) 7)	Claim(s) 1-17 is/are pending in the application. 4a) Of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-17 are subject to restriction and/or expressions.	wn from consideration.	
Applicati	on Papers	•	
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Example.	epted or b) objected to by the I drawing(s) be held in abeyance. See ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority u	ınder 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 			
Attachment	• •		
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da	
3) 🔲 Infom	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date		ratent Application (PTO-152)

Application/Control Number: 10/618,570 Page 2

Art Unit: 1646

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-11, drawn to an isolated protein, classified in class 530, subclass 350.

II. Claims 12-15, drawn to an isolated nucleic acid molecule, an expression vector,

and a method of producing a polypeptide, classified in class 536, subclasses

23.5 and 24.3; class 435, subclass 320.1, 325, and 69.1.

III. Claim 16, drawn to a method for the in vitro delivery of a molecule to a target site.

classified in class 514, subclass 1.

IV. Claims 16 and 17, drawn to a method for treating a disease in a patient

comprising administering to said patient a biotinylated molecule, classified in

class 514, subclass 1.

2. The inventions are distinct, each from the other for the following reasons. Inventions I

and II are unrelated. Inventions are unrelated if it can be shown that they are not

disclosed as capable of use together and they have different modes of operation,

different functions, or different effects (MPEP §806.04, MPEP §808.01). In the

instance case, the different inventions are drawn to completely different products, a

protein and a nucleic acid molecule. These molecules have completely different

structures and biological functions which are not interchangeable and which require

non-cohesive searches and considerations.

3. Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that

they are not disclosed as capable of use together and they have different modes of

operation, different functions, or different effects (MPEP §806.04, MPEP §808.01).

In the instance case the different inventions are drawn to completely different methods each having completely different method steps and having completely different outcomes. Thus, the methods are exclusive and require non-cohesive searches and considerations.

- 4. Invention I is related to Inventions III and IV as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP§806.05 (h)). In the instant case, a protein may be used to produce an antibody.
- 5. Invention II is related to Inventions III and IV as distinct inventions. The different inventions are drawn to distinct product and method inventions because the product cannot be used in the methods.
- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 7. Because these inventions are distinct for the reasons given above and the search required for a single group is not required for any other group, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48 (b) if one or more of the currently named inventors is no longer an inventor of at least one

Application/Control Number: 10/618,570

Art Unit: 1646

claim remaining in the application. Any amendment of inventorship must be

Page 4

accompanied by a petition under 37 CFR 1.48 (b) and by the fee required under 37

CFR 1.17 (I).

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Brenda Brumback, can be reached on (571) 272-0961. The fax number for

the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, please contact the Electronic

Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruisiung L. Ruisiang Li, Ph.D.

Primary Examiner

January 7, 2005